Major pharmaceutical companies including Novartis, Amgen, and Eli Lilly are focusing on a lesser-known type of cholesterol as a potential target for the next generation of blockbuster heart disease treatments. This form of cholesterol, considered particularly harmful, is being studied for its role in cardiovascular risk. The companies are developing drugs aimed at significantly reducing levels of this cholesterol, hoping to replicate the success of previous lipid-lowering therapies. If successful, these treatments could address unmet medical needs and capture a substantial market. The approach represents a shift toward more precise targeting of lipid subtypes beyond traditional LDL cholesterol. Clinical trials are underway to evaluate efficacy and safety, with early data showing promise. Analysts see this area as a key growth driver for cardiology portfolios, though regulatory and competitive hurdles remain.
Market Outlook
Novartis appears poised for near-term gains as its cholesterol-targeting pipeline advances, supported by strong trial momentum. However, regulatory risks could cap upside.
Source: CNBC Business
Disclaimer: this content is informational analysis only and does not constitute investment advice.
